Jennifer Maender, MD
Dermatology · Sugar Land, TXNPI 1962524371
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,850 of the $127,265 with a category attached, or 73.7%. Lilly USA, LLC accounts for 83.0% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $65,883, more than ten times the $3,435 reported in 2019. Among dermatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,185 payments — averaging $107.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$106K
- AbbVie$5K
- Johnson & Johnson$3K
- Novartis$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Incyte Corporation$1K
- plus $9K from 31 others
What the payments were for
- Speaking & faculty fees$93,85074%
- Travel & lodging$7,6566%
- Food & beverage$25,15020%
- Education$6080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 254 | $105,684 |
| AbbVie | 216 | $4,761 |
| Johnson & Johnson | 104 | $2,715 |
| Novartis | 105 | $2,148 |
| Regeneron Healthcare Solutions, Inc. | 74 | $1,839 |
| Incyte Corporation | 54 | $1,230 |
| Sanofi | 39 | $1,106 |
| Sun Pharmaceutical Industries Inc. | 38 | $919 |
| UCB, Inc. | 27 | $876 |
| E.r. Squibb & Sons, L.L.C. | 37 | $778 |
| Amgen | 40 | $766 |
| Galderma Laboratories, L.p. | 32 | $648 |
| Arcutis Biotherapeutics, Inc. | 29 | $621 |
| Biofrontera Inc. | 9 | $588 |
| LEO Pharma Inc. | 30 | $540 |
| Pfizer | 30 | $513 |
| Dermavant Sciences, Inc. | 14 | $348 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 11 | $189 |
| Aclaris Therapeutics, Inc. | 1 | $125 |
| Bristol Myers Squibb | 7 | $107 |
| Boehringer Ingelheim | 4 | $92 |
| Hill Dermaceuticals, Inc. | 1 | $86 |
| Eli Lilly | 1 | $79 |
| VYNE Pharmaceuticals Inc. | 4 | $60 |
| EPI Health, LLC | 3 | $58 |
| Almirall LLC | 3 | $57 |
| Organon | 3 | $40 |
| Verrica Pharmaceuticals Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Convatec Inc. | 1 | $32 |
| Mylan Pharmaceuticals Inc. | 2 | $31 |
| Journey Medical Corporation | 2 | $31 |
| Dermira, Inc. | 2 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $24 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$127,265 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 33 | $130,393 |
| OtezlaApremilast | 11 | $52,588 |
| Tacrolimus | 22 | $2,906 |
| Halobetasol Propionate | 57 | $2,371 |
| Ketoconazole | 176 | $2,329 |
| Triamcinolone Acetonide | 221 | $2,230 |
| Fluocinonide | 68 | $2,214 |
| Doxycycline Monohydrate | 113 | $2,210 |
| Tretinoin | 21 | $1,665 |
| Metronidazole | 41 | $1,488 |
| Fluorouracil | 15 | $1,319 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 25 | $1,211 |
| Calcipotriene | 12 | $1,082 |
| Betamethasone Dipropionate | 18 | $957 |
| Clobetasol Propionate | 33 | $937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $766 | $52,58811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,098 dermatology providers in Texas.
Other dermatology in Sugar Land
- Vandana MadkanSugar Land$327K
- Michael SonabendSugar Land$184K
- Edward LainAustin$2.5M
- William CragunSan Antonio$2.2M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
- Emily BeckerSan Antonio$1.2M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.